Collaboration with leading expert Dr. Robert Gemmill will support the company’s neuropilin-2 (NRP2) antibody program in oncology . SAN DIEGO , Oct. 29, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative

SAN DIEGO , Oct. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla , M.D., M.S., President and Chief Executive Officer,

Top line results are expected in the fourth quarter of 202 0 . Trial evaluating the preliminary safety and efficacy of ATYR1923 vs placebo has exceeded enrollment . SAN DIEGO , Oct. 26, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and

SAN DIEGO , Oct. 07, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will participate in two upcoming virtual investor events in

Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in Japanese healthy volunteers SAN DIEGO , Sept. 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel

Aspire Capital commits to purchase up to $20 Million of Common Stock over a period of up to 30 months. SAN DIEGO , Sept. 14, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel

SAN DIEGO , Sept. 09, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present at two investor conferences in September.

Company to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT  SAN DIEGO , Aug. 13, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological

Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy volunteers in Japan. SAN DIEGO , Aug. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel